In standard-of-care cancer therapies that involve platinum-based clinical agents, e.g., cisplatin or oxaliplatin, POLH can also bypass platinum-DNA adducts, negating the benefits of the treatment and enabling drug resistance [19,20,21,22,23,24,25,26,27]. This evidence concerns the gene POLH and cancer.